3152 results for «239»
3152 results
Mastering techniques from basic to complex - Advanced TAVI
13 Feb 2026 – From PCR Tokyo Valves 2026
Explore advanced TAVI techniques focusing on challenging patient subsets such as those with small annuli, bicuspid valves, and valve-in-valve procedures. This session reviews valve selection and procedural optimization to enhance clinical outcomes in complex scenarios.
Design that delivers the future of TAVI
13 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses future-oriented TAVI valve design and procedural planning. It highlights supra-annular valve benefits, strategies for managing concomitant coronary artery disease, and redo-TAVI approaches to ensure long-term durability and optimal hemodynamics.
Mastering LAA closure: a step-by-step case experience
14 Feb 2026 – From PCR Tokyo Valves 2026
This session presents a step-by-step, case-based approach to mastering left atrial appendage (LAA) closure. It covers pre-procedural planning, device-specific strategies, complication prevention, and complex bailout techniques such as leak closure with coiling or dual-device implantation.
Patient-tailored treatment for bicuspid valve
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on patient-tailored treatment for bicuspid aortic valve stenosis, providing comprehensive insights into the evidence base for TAVI in this population. It discusses critical considerations for valve selection and sizing, and highlights anatomical features that may pose challenges for TAVI procedures. Case studies illustrate...
Mastering mitral TEER: guidelines, complex cases, and Asia Pacific insights
14 Feb 2026 – From PCR Tokyo Valves 2026
This session provides an in-depth analysis of mitral transcatheter edge-to-edge repair (TEER) in light of the 2025 ESC Valvular Heart Disease guidelines. It addresses optimal timing and treatment strategies for severe heart failure beyond established trials, and explores technical solutions for complex anatomies. Special attention is...
Mitral TEER masterclass
14 Feb 2026 – From PCR Tokyo Valves 2026
This Mitral TEER masterclass focuses on addressing unique anatomical challenges encountered in Asian populations. The session covers device strategies and techniques tailored for complex anatomies, offering practical tips to minimize complications and improve procedural outcomes through detailed case analyses including small hearts, commissural prolapse with calcification,...
Real world outcomes and strategies for optimal TEER across diverse DMR anatomies
14 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the real-world complexities of degenerative mitral regurgitation (DMR) and presents advanced strategies for transcatheter edge-to-edge repair (TEER) using the PASCAL device. Participants will explore the latest registry data, device selection criteria, and tactical approaches to manage diverse and challenging DMR anatomies, aiming...
All you need to know about redo TAVI
15 Feb 2026 – From PCR Tokyo Valves 2026
This comprehensive session addresses the complexities of redo Transcatheter Aortic Valve Implantation (TAVI). It covers the full spectrum from pre-procedural analysis—including coronary obstruction risk and valve sizing—to procedural strategies like leaflet modification and optimal positioning. Post-procedural management including antithrombotic therapy and patient-prosthesis mismatch are also examined,...
News regarding the SIRONA Randomized Trial
10 Feb 2022
EuroPCR 2024: Primary outcomes from PINNACLE I clinical trial establish safety and effectiveness of Elixir Medical’s Hertz Contact Intravascular Lithotripsy System for calcium fragmentation in moderate to severe calcified coronary artery lesions
16 May 2024
TRILUMINATE pivotal: A landmark randomized clinical trial of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation
04 Mar 2023
Jonathan Curio and Alex Sticchi provide their take on this clinical trial which was presented by Paul Sorajja at the American College of Cardiology Scientific Session (ACC.23/WCC).

Author

Author
BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.
04 Mar 2024